Nasdaq

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through ...
Seeking Alpha

EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal

EyePoint Pharmaceuticals, Inc. EYP-1901, a potential treatment for wet age-related macular degeneration, showed positive results in a Phase 2 study, meeting primary and secondary endpoints. The drug ...
News Medical

Study hints at a promising approach for treating wet age-related macular degeneration

A new study in mice hints at the promise of an eventual alternative treatment option for the "wet" version of age-related macular degeneration (AMD). Researchers determined in mice that an enzyme ...
Nasdaq

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...
Healio

Enrollment underway in phase 2 study of subcutaneous anti-VEGF wet AMD, DME candidate

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first patient has been enrolled in a two-stage phase ...
Seeking Alpha

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Ocular to Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (OCUL) (NASDAQ: OCUL, “Ocular”, the ...